UBS AM’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

UBS AM’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-20,097	Closed	-$182K	–	2607
2013 Q4	$182K	Sell	20,097 -13,200	-40%	-$95.3K	﹤0.01%	2400
2013 Q3	$210K	Hold	33,297	–	–	﹤0.01%	2309
2013 Q2	$227K	Buy	+33,297	New	+$232K	﹤0.01%	2193

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM's CADX Position: Q1 2014 in Review

UBS AM sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 20,097 shares — an estimated $182K sold.

UBS AM first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $227K in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

UBS AM reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
UBS AM sold 20,097 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $182K.
UBS AM first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
UBS AM's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $227K in Q2 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on UBS AM's 13F filing for Q1 2014, filed 23 May 2014.